Login
$AQST
$3.76 +$0.00 (0.04%) After hours

$AQST SEC Filings

Filed On Filing
16 Nov 2026 Form 4
16 Nov 2026 8-K: Regulation FD Disclosure

________________________________________________________________________________________________________________________

12 Nov 2026 144
12 Nov 2026 Form 4: Daly Richard J, Director

Bought 28,025 shares ($99.3K)

12 Nov 2026 Form 4: Davis Matthew W., Chief Development Officer

Gave up 5,303 shares to cover exercise price or tax ($18.7K)

10 Nov 2026 Form 4: Daly Richard J, Director

Granted 57,000 Non-Qualified Stock Option (right to buy)

05 Nov 2026 8-K: Regulation FD Disclosure

Disclaimer This presentation and the accompanying oral commentary have been prepared by Aquestive Therapeutics, Inc. (“Aquestive,” the “Company,” “we,” “our” or “us”) and contain “forward-looking statements” within the meaning of the Pri...

03 Nov 2026 10-Q
03 Nov 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Warren, N.J., November 3, 2026 – Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a biopharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science, t...

23 Oct 2026 Form 4: Cochran John, Director

Acquired 62,229 shares (Other Transaction)

19 Oct 2026 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year

150023820.2 AMENDED AND RESTATED BYLAWS OF AQUESTIVE THERAPEUTICS, INC. (As of October 1516[●], 20242026) ARTICLE I STOCKHOLDERS Section 1. The annual meeting of the stockholders of Aquestive Therapeutics, Inc. (the “Corporation”) for th...

16 Oct 2026 Form 4: Barber Daniel, Director

Sold 25,000 shares ($106K)

16 Oct 2026 Form 3: Daly Richard J, Director

Holds 0 shares of Common Stock

15 Oct 2026 8-K: Regulation FD Disclosure

Aquestive Therapeutics Announces FDA Acceptance of Anaphylm™ NDA Resubmission and PDUFA Goal Date of March 16, 2027 • FDA accepted the resubmission as complete and classified it as a Class 2 response • Prescription Drug User Fee Act (PDU...

14 Oct 2026 8-K: Entry into a Material Definitive Agreement

Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal Film • Differentiated, portable buccal film would offer patients and caregivers an alternative to existing nasal...

07 Oct 2026 SCHEDULE 13G
07 Oct 2026 SCHEDULE 13G/A
29 Sep 2026 8-K: Departure/Election of Directors or Officers; Compensation

Aquestive Therapeutics Strengthens Board of Directors with Appointment of Richard Daly Appoints Rich Daly, a life sciences executive with more than 30 years of leadership experience across large pharmaceutical companies, emerging biotech...

25 Sep 2026 8-K: Regulation FD Disclosure

Disclaimer This presentation and the accompanying oral commentary have been prepared by Aquestive Therapeutics, Inc. (“Aquestive,” the “Company,” “we,” “our” or “us”) and contain “forward-looking statements” within the meaning of the Pri...

17 Sep 2026 8-K: Regulation FD Disclosure; Other Events

H.C. Wainwright 28th Annual Global Investment Conference September 14, 2026

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support